Drugs-for-lipid-regulation
The Lancet
Diabetes & Endocrinology: Published: March, 2024Atherosclerotic cardiovascular
disease is a leading cause of death worldwide, and LDL cholesterol is a major
causal risk factor.Diabetes substantially increases
the risk of atherosclerotic cardiovascular disease.TAKE-HOME MESSAGEIn this
participant-level meta-analysis of 19 trials, sta...
Circulation: Cardiovascular Quality and Outcomes: Published
Apr 2024TAKE-HOME MESSAGEThis study
used data from the FAST-MI program to examine the effect of lipid-lowering
therapy (LLT) (atorvastatin ≥40 mg or equivalent or any combination of a statin
and ezetimibe) intensity on long-term mortality in 2258 patients aged 80 years
or older who ex...
Clinical Gastroenterology and Hepatology: February,
2022The incidence rate of
hepatocellular carcinoma (HCC) has been increasing for the last 3 decades. Fatty liver
progresses from fat accumulation to inflammation to fibrosis to cirrhosis to
cancer. Recent evidence suggests potential clinical
benefits of statin in cancer chemoprevention a...
European Heart Journal: September, 2022Cardiovascular (CV) disease (CVD) is the leading cause of
morbidity and mortality worldwide, despite continuous improvement of medical
treatment, diagnosis, and risk factor control. It has been clearly
demonstrated that statin therapy confers significant mortality and morbidity
benefits in both the primary...
JAMA Cardiology: Published on November, 2022TAKE-HOME MESSAGEQuestion: Does vitamin D prevent statin-associated muscle
symptoms and reduce statin discontinuation?This study assessed whether vitamin D supplementation (2000
IU of cholecalciferol) would prevent statin-associated muscle symptoms (SAMS)
and reduce statin discontinuation in 2083 part...
AHA Journal: Circulation: Published on February,
2023Low-density lipoprotein cholesterol
(LDL-C) level is a well-established risk factor for atherosclerotic
cardiovascular disease. However, the optimal achieved LDL-C level with regard
to efficacy and safety in the long term remains unknown.TAKE-HOME MESSAGEThis study assessed the
relationship...
JAMA Internal MedicineTAKE-HOME MESSAGEThis retrospective study evaluated
the association between statin initiation and diabetes progression. Progression
of diabetes occurred in significantly more statin users. There was a
dose–response relationship with higher-intensity statin use.The study examined 12 years of data
on patients covered by the...
STATIN SELECTION
A. Dosage & Administration
At the start dose and following
dose titration, rosuvastatin was
significantly more effective than atorvastatin
at reducing LDL-C and achieving European LDL-C goals in patients with type 2 diabetes.
Key Notes
The...
Statins, also known as HMG-CoA
reductase inhibitors, are a class of lipid-lowering medications that reduce
illness and mortality in those who are at high risk of cardiovascular disease.
They are the most common cholesterol-lowering drugs. RemoveAvailable Brand
American College of
Cardiology/American Heart Association Task Force Clinical Practice Guidelines
identifies high- intensity and moderate-intensity statin therapy for use in
primary and secondary prevention of Cardiovascular disease.
When choosing a
statin dose, expected LDL reduction is not the only...
UMHS Lipid Therapy
Guideline Recommendations (2014)
The guidelines showed that Rosuvastatin
is the most potent statins with respect to lowering LDL, followed by
atorvastatin, pitavastatin, simvastatin and lovastatin.
Rosuvastatin 40 mg reducing LDL cholesterol by
63% whereas Atorvastatin 80...
C. Insulin
resistance:
Lipophilic
statins may have adverse metabolic consequences that include impaired
insulin secretion and promotion of insulin resistance.
Hydrophilic
statins
·
pravastatin improves insulin sensitivity in some
patients...